Patent US4921690A successfully refreshed from Google Patents.
US4921690A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of enhancing the biodistribution of antibody for localization in lesions
Assignee: City of Hope
•
Filing: 1988-04-12
•
Granted: 1990-05-01
•
Expires: 2008-04-12
Abstract
Abstract A method for enhancing the biodistribution of antibody for localization in lesions comprising initially exposing a mammalian subject containing lesion-associated marker substance to a first antibody specific for a given epitope of the marker substance, and after a period of time such that the marker substance has associated with the antibody, exposing the mammal to a further amount of the same antibody, or a second antibody specific either for an epitope of the marker substance different from the epitope for which the first antibody is specific, or for the same epitope of the marker substance as the first antibody but of a different binding affinity from the first antibody.
Inventors
- 👤 John D. Beatty
- 👤 Barbara G. Beatty
- 👤 Rosemary B. Duda
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 03:46
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1084; A61K51/1087; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6875; A61K47/6877; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/1027; A61K2123/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
124 words
A method for enhancing targeting of a lesion near the liver or spleen of a mammalian subject by administration of a labeled monoclonal antibody specific for a marker substance for said lesion which comprises: preselecting a combination of unlabeled and detectably labeled lesion marker substance specific monoclonal antibodies, the relative proportion of said unlabeled monoclonal antibodies in said combination being sufficient to substantially clear said lesion marker substance form the bold in circulation in said subject and to provide labeled monoclonal antibody for accumulation is said lesion, and administering said combination of labeled and unlabeled monoclonal antibodies to said mammalian subject in an amount at least sufficient to provide enhanced targeting of said lesion by accumulation of said labeled monoclonal antibody in said lesion.
Claim 2
Independent Claim
124 words
A method for enhancing targeting of a lesion near the liver or spleen of a mammalian subject by administration of a labeled monoclonal antibody specific for a marker substance for said lesion which comprises: preselecting a combination of unlabeled and detectably labeled lesion marker substance specific monoclonal antibodies, the relative proportion of said unlabeled monoclonal antibodies in said combination being sufficient to substantially clear said lesion marker substance form the bold in circulation in said subject and to provide labeled monoclonal antibody for accumulation is said lesion, and administering said combination of labeled and unlabeled monoclonal antibodies to said mammalian subject in an amount at least sufficient to provide enhanced targeting of said lesion by accumulation of said labeled monoclonal antibody in said lesion.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said monoclonal antibodies are monoclonal antibodies of mammalian origin.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein said antibody is T84.66 and said label is indium-111.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein said first antibody is T84.66 and said second antibody is ZCE025.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein said antibody is a chimeric antibody of murine/human origin.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein said unlabeled or labeled monoclonal antibodies are administered simultaneously.
Claim 8
Dependent Claim
13 words
The method of claim 6 wherein said monoclonal antibody mixture is administered intravenously.
Claim 9
Dependent Claim
22 words
The method of claim 1 wherein said lesion-associated marker substance is oncofetal antigen, tumor antigen, a receptor, a hormone, or an enzyme.
Claim 10
Dependent Claim
12 words
The method of claim 8 wherein said lesion-associated marker substance is CEA.
Claim 11
Dependent Claim
16 words
The method of claim 1 wherein said monoclonal antibodies are fragments of mammalian origin monoclonal antibodies.
Claim 12
Dependent Claim
16 words
The method of claim 1 wherein said monoclonal antibodies are chimeric monoclonal antibodies of mammalian origin.
Claim 13
Independent Claim
14 words
The method of claim I wherein said labeled monoclonal antibody comprises a detectable agent.
Claim 14
Dependent Claim
11 words
The method of claim 12 wherein said detectable agent is indium-111.
Claim 15
Dependent Claim
20 words
The method of claim 1 wherein said unlabeled antibody is administered prior to the administration of said labeled monoclonal antibody.
Claim 16
Dependent Claim
29 words
The method of claim 14 wherein said unlabeled monoclonal antibody is administered to said mammal between about 20 minutes and 7 days prior to administration of said labeled antibody.
Claim 17
Dependent Claim
19 words
The method of claim 14 wherein said unlabeled monoclonal antibody is administered to said subject in a single dose.
Claim 18
Dependent Claim
20 words
The method of claim 14 wherein said unlabeled monoclonal antibody is administered to said subject in multiple doses over time.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-30 | 1993-10-30 | 1994-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-30 | 1997-10-30 | 1998-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-30 | 2001-10-30 | 2002-05-01 | $7700.00 | Window Closed / Lapsed |